Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ADMP seeing CRT Capital reiterates $15 stating selloff way overdone don't have access to report anyone ??? thanks in advance...
ADMP yes much lower vol then yesterday deeply oversold adding trading shares for scalp great entry below offering at $5.95
ADMP your welcome & looking like great entry 4 you GLTY & make $$$$$$$$
ADMP heck was $6.90 9 trading days ago lol geez
ADMP maybe final flush as financier been in control since Dec offering keeping it rangebound.... s/b great entry below offering price hasn't been there since Dec & 60 mill dollar market cap for 8 drug pipeline & 1 NDA & 3 phase 3 drugs
ADMP Oversold & Bottom of range DD post.New Buy Coverage started $15 Target DD on ADMP tiny Biotech co. 10.3 mill shares out & float of 4.7 Mill shares..here are some facts.. 63 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition, enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
Follow the Big Money Vol higher last 3 days..Impressive Institutional buying since Dec 45% of total shares out bought & Insiders own almost 1 mill more leaving a float approx 4.7 mill shares & shrinking every week !!!!!!!!!!!!
TOTAL Institutional holdings = 4,653,334 shares out of 10.3 million total outstanding & Insiders almost 1 million shares held....Best part is majority of new institutions have bought all these shares the last 8 weeks !!!!
ESES holdings 1,741,973 shares .......see 13G filing as not on Institutional list yet
CRT Capital 513,628 shares........see 13g filing as not on Institutional list yet
GEMINI Fund 375,130 shares .......see 13G filing as not on Institutional list yet
MARXE AUSTIN 525,000 shares
SABBY MGT 407,024 shares
GROW PARTNERS 325,000 shares
GRANITE POINT 205,000 shares
BARD ASSOC 170,925 shares
SCOGGIN LLC 150,000 shares
DAFNA CAPITAL 125,000 shares
+ 8 other smaller holders
ADMP the street article out 3 Bio's to watch for breakout INO & ADMP 2 of them link
http://www.thestreet.com/story/12558139/3/3-biotech-stocks-under-10-to-trade-for-breakouts.html
ADMP once $7 breaks & holds it's off to double digits Bob wayyyy too cheap at 68 million dollar market cap for 9 drug pipeline & multiple Billion dollar markets
ADMP once $7 breaks & holds it's off to double digits Bob wayyyy too cheap at 68 million dollar market cap for 9 drug pipeline & multiple Billion dollar markets
ADMP finally waking up last few days on better volume Institutional ownership keeps rising.... see prior post for some DD
ADMP long a bunch for the following catalysts. #1 Valuation is ridiculous 64 million dollars for a 9 drug pipeline is insane. #2 NDA for generic Epipen s/b out any day & generating revenues early 2015.#3 Generic Advair trials this summer & entering an untapped 6 + Billion dollar market. #4 possible partnerships this year. #5 After many conversations with ADMP imo I wouldn't be surprised to see ADMP spin off the Biotech side from the specialty generic side giving shareholders 2 companies for the price of current one which will unlock a much higher valuation. #6 Valuation lol I know already listed but deserves to be listed twice. Gotta also appreciate the large quick rise in Institutional ownership going from 1 or 2 holders in November to current 18 & garnering over 45% of total shares out plus Insiders owning almost 1 million shares leaving a very small float under 5 million shares. I think once this train gets going it will garner a quick ride higher imo. GLTA & make $$$$$$$$$$$$$$$$$$$$$$$$$$$
ADMP 9 Days down finally Oversold easy bounce as at bottom of 3 month support = BUY TIME DD New Buy Coverage started $15 Target DD on ADMP tiny Biotech co. 9.9 mill shares out & float of 7.3 Mill shares..spent 50 mins on phone with management Fri & here are some facts.. 65 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition, enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
Follow the Big Money Vol higher last 3 days..Impressive Institutional buying since Dec 45% of total shares out bought & Insiders own almost 1 mill more leaving a float approx 4.7 mill shares & shrinking every week !!!!!!!!!!!!
TOTAL Institutional holdings = 4,653,334 shares out of 10.3 million total outstanding & Insiders almost 1 million shares held....Best part is majority of new institutions have bought all these shares the last 8 weeks !!!!
ESES holdings 1,741,973 shares .......see 13G filing as not on Institutional list yet
CRT Capital 513,628 shares........see 13g filing as not on Institutional list yet
GEMINI Fund 375,130 shares .......see 13G filing as not on Institutional list yet
MARXE AUSTIN 525,000 shares
SABBY MGT 407,024 shares
GROW PARTNERS 325,000 shares
GRANITE POINT 205,000 shares
BARD ASSOC 170,925 shares
SCOGGIN LLC 150,000 shares
DAFNA CAPITAL 125,000 shares
+ 8 other smaller holders
ADMP long a bunch for the following catalysts. #1 Valuation is ridiculous 64 million dollars for a 9 drug pipeline is insane. #2 NDA for generic Epipen s/b out any day & generating revenues early 2015.#3 Generic Advair trials this summer & entering an untapped 6 + Billion dollar market. #4 possible partnerships this year. #5 After many conversations with ADMP imo I wouldn't be surprised to see ADMP spin off the Biotech side from the specialty generic side giving shareholders 2 companies for the price of current one which will unlock a much higher valuation. #6 Valuation lol I know already listed but deserves to be listed twice. Gotta also appreciate the large quick rise in Institutional ownership going from 1 or 2 holders in November to current 18 & garnering over 45% of total shares out plus Insiders owning almost 1 million shares leaving a very small float under 5 million shares. I think once this train gets going it will garner a quick ride higher imo. GLTA & make $$$$$$$$$$$$$$$$$$$$$$$$$$$
ADMP low vol sale going on imo 64 Mill $$ Mkt Cap is nuts
ADMP s/b perking up soon NDA PR any day & expecting few articles on ADMP soon... Timing is setting up now over 10 weeks since uplisting & offering just about there for launch out of this basing area....Just too cheap for their prospects & deep pipeline 67 million dollars is a joke...
ADMP Bob reminds me of TNXP took 12 weeks for TNXP to get cut loose & ADMP going on 10 weeks with better volume s/b any day this tiny float gets loose... ADMP's deep pipeline of Billion dollar opportunities justifies a market cap of a laughable 100 million = $10 a share ... IMO only ADMP will be a big multi bagger for patient longs in 2014
ADMP also has DNDN type cell based vaccine TeloB-VAX again deep pipeline... for 68 Million dollar market cap ???? not for long imo being found.
http://www.businesswire.com/news/home/20110419005681/en/Adamis-Completes-Acquisition-Technology-Potential-Universal-Cancer#.UwjqwIWsTzJ
SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California. The patent comprises “Composition and Method for Inducing and Enhancing a Telomerase Reverse Transciptase-Reactive Cytotoxic T Lymphocyte Response.” The technology was discovered and developed by Maurizio Zanetti, M.D., at the University of California, San Diego (UCSD). In addition to this license, Adamis licensed a complementary patent, “Cancer Immunotherapy and Diagnosis Using Universal Tumor Associated Antigens, Including Human Telomerase Reverse Transciptase,” based on similar technology from the Dana-Farber/Harvard Cancer Center. This technology constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, which activates the body’s natural defense machinery to stimulate an immune response against one of nature’s universal tumor markers, i.e. telomerase. The vaccine utilizes the patient’s own B cells as antigen producing and antigen presenting cells. B cells represent approximately 12% of the circulating blood cells.
“Cancer Immunotherapy and Diagnosis Using Universal Tumor Associated Antigens, Including Human Telomerase Reverse Transciptase”
Dr. Zanetti, Professor of Medicine and Director of the Laboratory of Immunology at the UC San Diego Moores Cancer Center, stated of the TeloB-VAX vaccine, “It is the first concrete opportunity to program the immune system to mobilize killer lymphocytes to combat cancer cells, whether these are adult differentiated cells or progenitor cancer stem cells. Since telomerase is increased in over 85% of all cancers, the vaccine can potentially be used to treat multiple cancer types, such as breast, lung, and colon cancer. It can truly be considered a platform therapeutic vaccine technology. It is like the polio vaccine for cancer.”
Adamis’ therapeutic cancer vaccine is conceptually distinct from the only FDA approved cell-based cancer vaccine, Provenge, developed by Dendreon Corporation (NASDAQ: DNDN). Adamis’ TeloB-VAX vaccine is composed of the patients’ own circulating B lymphocytes harboring a unique patented engineered plasmid DNA. The transfection (plasmid DNA entering the B cell) procedure is “spontaneous,” requiring no facilitating molecules or devices. After 60 minutes of incubation with the plasmid, the cells can be re-infused back into the patient. TeloB-VAX prostate cancer vaccine has been shown to induce a potent cellular immune response against the first truly common cancer marker, the telomerase reverse transcriptase (TERT). Telomerase was the subject of the Nobel Prize for Medicine in 2009.
A Phase 1 study completed at UCSD in castrate resistant prostate cancer (CRPC) patients demonstrated this vaccine to be safe, non-toxic and immunogenic. Two injections of TeloB-VAX, spaced one month apart, were shown to induce a specific CD8 T cell response. More important, the T cells induced post vaccination were shown to specifically kill prostate cancer cells.
Adamis believes the UCSD and Harvard technology offers some significant advantages over the existing FDA approved vaccine, Provenge. Some of the advantages include: 1) prolonged antigen presentation by B cells (5 days) as compared to the short presentation time by dendritic cells (12 hours); 2) a unique patented platform technology using a universal cancer antigen (marker) that is increased in approximately 85% of all tumors; 3) induces an immune response after a single injection; 4) no need for complicated culture procedures; 5) much fewer steps; and, 6) lower cost. TeloB-VAX may prove to be called a “universal cancer vaccine” that could induce immunity against multiple cancer types as well as targeting the specific cancer stem cell.
Telomerase is an enzyme that adds DNA sequence repeats (e.g., "TTAGGG") to the 3’ end of DNA strands in the telomere regions of chromosomes at every cell division. Telomerase confers the immortality trait that converts normal cells into cancer cells and prevents the erosion of telomeres and end-to-end chromosomal fusion. As such, telomerase is over-expressed in the vast majority of differentiated cancer cell types. Importantly, telomerase is also necessary for self-renewal of cancer stem cells and cancer cell progenitors. Based on the foregoing, TERT is an antigen or tumor marker expressed in both differentiated and progenitor cancer cells making vaccination against TERT a potentially effective measure to induce an immune response against cancer cells at both stages of differentiation.
Dr. Dennis J. Carlo, President and CEO of Adamis Pharmaceuticals, stated: “We continue to add significant assets to our cancer franchise. Our telomerase therapeutic cancer vaccine could very well prove to be pivotal in the treatment of many types of cancer. Telomerase is probably the closest to any universal tumor marker that we know of today. Attacking telomerase and effectively interfering with its biologic activity could very well be the key to the treasure in inhibiting the growth of cancer cells.”
Adamis has recently contracted for the manufacture of additional plasmid in preparation for expanding the clinical studies in prostate cancer patients. Please see Adamis’ website for a short animated video describing and explaining the TeloB-VAX process and procedure (www.adamispharma.com).
ADMP Bob I have spoken to original author & he is working on an updated article as well. Being that ADMP was a BB stock & not followed at all with little to no institutional sponsorship, wow has that changed the last 9 weeks now Institutions own 45% & growing quickly & a float under 5 million shares. Here is the original November article
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
ADMP Bob really seems since the updated Institutional #'s came out & the fact they sucked up 45% of the total shares out since Dec is pretty impressive & telling where ADMP is headed besides being dirt cheap 66 million dollars lol...Every $1.00 ADMP goes up in share price only adds 10 million to their market cap
ADMP is a pre filled syringe not an auto injector so wont be affected...
http://www.adamispharmaceuticals.com/products-epinephrine-pfs.php
ADMP near term Catalysts are NDA filing any day for generic Epipen, phase 3 trial generic Advair with newly acquired 3M inhaler & phase 3 trial on APC-1000 inhaled oral steroid for the treatment of asthma and COPD. Beximco is their partner on that one so s/b a busy 2014. Bottom line at 65 million dollar market cap with deep pipeline & potentially entering multiple different Billion dollar markets = one dirt cheap stock that no one knows about ..... except about 15 new Institutions loading up lol.... GLTY & make $$$$$$$$$$$
ADMP agreed 100% LINK to $15 target & 22 pages of research... best part about this report is Analyst had to DUMB down the numbers to get down to $15 target... He assigned less then 2% of the Advair market to ADMP & NOTHING at all for Bio side....If he used normal projections his price target would have been so high all would say it was laughable.....
https://docs.google.com/file/d/0Bwgu6jYVrAKiZDVfRWpPZ2E4b0hOc2p0LUZ5MlA4OFFxM0xj/edit?pli=1
TNXP impressive run $4's to $21 similar float & same recent Naz uplist ADMP imo may have a similar type run this year.. GLTA & make $$$$$$$$$$$$$$$$$$
ADMP another new Institutional buyer GROW PARTNERS 325,000 shares bring total Institutions over 4.65 million shares plus Insiders almost 1 million shares of 10.3 million total out & again ALL new Tute buyers in last 8 weeks !!!!!!!! shares getting locked down.
ADMP Updated Institutional ownership = almost 44% of shares out... 4.34 Mill shares of 10.3 mill plus insider ownership of approx 1 mill shares as well....Keep in mind all the Institutional ownership has occurred in the last 8 weeks !!!!! as ADMP was .40 cents on BB before Dec uplisting, reverse split and offering all in 1 shot. Seems Tutes are accumulating lots of shares as far too cheap at 63 million dollar market cap for deep pipeline entering billion dollar markets
top holders are
ESES Holdings at 1.74 Mill shares
MAX AUSTIN & GREENEHOUSE 525,000
CRT CAPITAL 514,000
SABBY MGT 407,000
GEMINI FUND 375,000
GRANITE POINT MGT 205,000
BARD ASSOC 171,000
+ 9 others
2 new 13 G institutional owners CRT capital 513K & Gemini fund 375K also of note updated Institutional ownership = almost 44% of shares out... 4.34 Mill shares of 10.3 mill plus insider ownership of approx 1 mill shares as well....top holders are
ESES Holdings at 1.74 Mill shares
MAX AUSTIN & GREENEHOUSE 525,000
CRT CAPITAL 514,000
SABBY MGT 407,000
GEMINI FUND 375,000
GRANITE POINT MGT 205,000
BARD ASSOC 171,000
+ 9 others
ADMP my bad 3rd filing missed CRT Capital 14% owned wow shares getting sucked up fast...
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204-14-009868.txt&FilePath=\2014\02\14\&CoName=ADAMIS+PHARMACEUTICALS+CORP&FormType=SC+13G&RcvdDate=2%2F14%2F2014&pdf=
ADMP 2nd 13G Institutional owmer filing in a week 9% of shares out sucked up small float & deep pipeline for 63 million dollar market cap Bio ...remember 3M that 95 Billion dollar titan is their partner on new advair inhaler that ADMP now owns from 3M
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001213900-14-000940.txt&FilePath=\2014\02\14\&CoName=ADAMIS+PHARMACEUTICALS+CORP&FormType=SC+13G%2FA&RcvdDate=2%2F14%2F2014&pdf=
ADMP $6.25 been a great area to buy s held this area couple of times & NDA filing news coming soon
ADMP agreed at 63 million $$ market cap & deep pipeline seems crazy cheap here & only 1 way to go GLTY & make $$$$$$$$ BTW 95 Billion dollar 3M as partner makes me feel so good waiting this one out
ADMP back in buy area..New Buy Coverage started $15 Target DD on ADMP tiny Biotech co. 9.9 mill shares out & float of 7.3 Mill shares..spent 50 mins on phone with management Fri & here are some facts.. 65 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition, enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
ADMP solid since offering & New Buy Coverage started $15 Target DD on ADMP tiny Biotech co. 9.9 mill shares out & float of 7.3 Mill shares..spent 50 mins on phone with management Fri & here are some facts.. 65 million $$$ market Cap for any biotech is very cheap but for a pipeline like ADMP's is insanely cheap. Biggest news imo is Tier 1 giant 95 Billion dollar 3M is their partner on newly purchased inhaler asset developed over 10 years by 3M. 3M retains all manufacturing rights & inhaler rights outside of drug sector. ADMP can license the inhaler to other drug co.s & pursue their own drugs. First objective is Glaxo's Advair which ADMP will file a 505b & make a generic Advair product. Currently Glaxo is all alone even though Advair came off patent 3 years ago as Advair uses a dual drug & others have found it extremely difficult to produce including TEVA who gave up. Advair enjoys worldwide sales over 8 bill $$$ & over 6 Billion in the U.S. alone. In Sept the FDA lowered guidelines to try & advance a generic Advair product so FDA wants competition in the market a huge plus... also the drug data by Glaxo will be used by ADMP so time to market will be much shorter then starting from scratch. When asked I was told between manufacturing compliance 6 to 8 months & phase 3 trials which will consist of 12 weeks but of course FDA paperwork, trial composition, enrollment and data results seems like 2nd quarter 2015 ADMP will submit NDA & early 2016 hitting the market. I know that seems a long time away but remember entering a 6 billion dollar U.S. market & sure to capture imo a large % due to much lower prices but even conservative 20 to 25% would be well over 1 Billion in sales. What valuation would a co. doing those types of sales value at in the market ? ADMP is at 65 Million dollar market cap. I would say they are cheap if this were the ONLY product they have BUT wait lets look at pipeline.
Epinepherine aka Epi pen s/b approved late 2014 as NDA filing in 1st Qtr
APC-1000 HFA branded generic inhaled oral steroid for asthma Phase 3 Trials 2.7 Bill $$$ Market
APC-3000 for Allergic Rhintis HFA Generic inhaled Nasal Steroid Phase 3 Trial 4 Bill $$$ market
APC 100 & 200 Prostate drugs currently in Phase 1 & obtained from University of Wisconsin.
TeloB-Vax an Immune based therapy in Phase 2 & basically it works by telling the bodies own immune system to create custom T-cells & kills up to 85% of all cancers. Better description here
http://www.adamispharmaceuticals.com/products-telob-vax.php
C31G a spermicide that according to co. is looking for partner for final leg & FDA submission.
CASH & DEBT ... Always a concern for me on Bio's is cash, cash burn & future dilution well take a look at recent financing done by ADMP. I was told they had Multiple deals on the table once 3M product was secured & a very nice deal indeed... First thing that jumped out at me was NO Warrants in deal a clean financing done. Over allotment s/b a done deal & leaves ADMP with approx 11+ Mill $$$$ & that's after paying off 3M & Convertible Note Holders of some 7.2 million... The only dilution out there is some 800K warrants from June priced at $5.95 a share so would land ADMP another 4.9 mill in Cash if exercised. That's it CLEAN & NO debt. Management also feels license deals may develop in 2014 adding cash to the balance sheet as well & was told worse case no warrant dollars & no license deal they s/b fine cash wise to the end of 2014 early 2015.
Well some other links to further DD & listing great 3M data on newly acquired inhaler..
http://seekingalpha.com/article/1868881-adamis-pharmaceuticals-two-companies-for-the-price-of-one?source=yahoo
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314037544000&locale=en_WW&assetType=MMM_Image&assetId=1273684149733&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314026034000&locale=en_WW&assetType=MMM_Image&assetId=1273685196267&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1314027541000&locale=en_WW&assetType=MMM_Image&assetId=1273684150144&blobAttribute=ImageFile
http://solutions.3m.com/3MContentRetrievalAPI/BlobServlet?lmd=1316792825000&locale=en_WW&assetType=MMM_Image&assetId=1273695579274&blobAttribute=ImageFile
Last but not least FDA lowers guidelines for Generic Advair huge plus for ADMP going forward
http://www.ft.com/cms/s/0/33dd6cd6-1a2f-11e3-b3da-00144feab7de.html#axzz2pSXapSG7
ADMP been rock solid since $5.95 offering & basing well above $6.50 avg.... should begin climbing very soon as many news items coming & financiers s/b done moving shares soon imo....setup looks great
ADMP Briefing just out. Adamis Pharma initiated with a Buy at CRT Capital; tgt $15 (6.68)
CRT Capital initiates ADMP with a Buy and target of $15. Having recently acquired the exclusive rights to 3M's multi-dose dry powder inhaler (DPI), CRT believes there is the potential for Adamis to develop a competing product to GSK's Advair Diskus by 2017. Adamis intends to use the 505(b)2 regulatory pathway, which could cut down on the development costs, and shorten the time to market. Adamis plans on beginning clinical trials for its dry powder inhaler (named APC-5000) in mid-14. CRT believes ADMP shares could benefit as the Co moves into clinical trials with 2 of its 3 respiratory treatments in 2014.
ADMP CRT Capital out with $15 target & research only the first to start coverage
http://www.streetinsider.com/Hot+New+Coverage/CRT+Capital+Starts+Adamis+Pharmaceuticals+%28ADMP%29+at+Buy/9092902.html
ADMP nice reversal off $6.20 alerts earlier see DD posts
ADMP now 62 Million $ market Cap low vol selloff & keep in mind a very deep pipeline , has cash till 2015 & has 95 Billion dollar 3M as partner on generic advair inhaler... ADMP looking to generate revenues by years end on generic Epi-pen & Telovax entering phase 2 trials insanely cheap Biotech imo....
ADMP Immunotherapy news out this a.m. & only part of ADMP deep pipeline. Immunotherapy is red hot & keep in mind generic Epi pen s/b approved later this year & generating Rev's & Generic Advair trials later this year & NDA next ... ADMP has multiple billion dollar markets looking to enter all for 68 Million dollar market cap ???
http://finance.yahoo.com/news/adamis-receives-notice-key-allowance-130000803.html
ADMP chart setting up perfectly continues walking higher & been solidly above $5.95 offering done in Dec. At 68 million dollar market cap for their deep pipeline & especially newly acquired 3M inhaler & now has 95 Billion dollar 3M as their partner going forward with 3M retaining all manufacturing rights & looking to enter 8 Billion dollar Glaxo Advair market as first generic target for inhaler.